Levofloxacin — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Bacterial Infections

• Amoxicillin
• Azithromycin
• Ciprofloxacin
• Doxycycline
• Metronidazole

Other medications in Infectious Disease

• Molnupiravir
• Nirmatrelvir/Ritonavir
• Nitrofurantoin
• Sofosbuvir/Velpatasvir
• Trimethoprim
• Bictegravir/Emtricitabine/TAF
• Dolutegravir/Lamivudine
• Elbasvir/Grazoprevir

About Levofloxacin

Levofloxacin is a potent antibiotic used to combat a wide range of serious bacterial infections, helping you recover and get back to your best. Understanding this crucial medication is key, and at TheDrugClub, we believe accessing life-saving prescriptions shouldn't break the bank.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Levofloxacin is approved for (FDA label)

Levofloxacin tablets are a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated ( 1 , 12.4 ).

Source: Read the full FDA label on DailyMed. Label effective date: September 1, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Levofloxacin (FDA label)

WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions (5.1) ], including: Tendinitis and tendon rupture [see Warnings and Precautions (5.2) ] Peripheral neuropathy [see Warnings and Precautions (5.3) ] Central nervous system effects [see Warnings and Precautions (5.4) ] Discontinue levofloxacin immediately and avoid the use of fluoroquinolones, including levofloxacin, in patients who experience any of these serious adverse reactions [see Warnings and Precautions (5.1) ] Fluoroquinolones, including levofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid levofloxacin in patients with a known history of myasthenia gravis [see Warnings and Precautions (5.5) ]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1 to 5.15) ], reserve levofloxacin for use in patients who have no alternative treatment options for the following indications: Uncomplicated urinary tract infection [see Indications and Usage (1.12) ] Acute bacterial exacerbation of chronic bronchitis [see Indications and Usage (1.13) ] Acute bacterial sinusitis [see Indications and Usage (1.14) ]. WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS See full prescribing information for complete boxed warning.

Source: FDA prescribing information (DailyMed). Set ID: 5a65b2bc-9edc-f193-e063-6394a90a0104. SPL document ID: 5a65b2c4-0961-618e-e063-6294a90aefaa. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Levofloxacin (FDA label)

Levofloxacin tablets USP, 250 mg are terra pink colored capsule shaped, biconvex film-coated tablets, debossed with ‘13’ on one side and ‘T’ on the other side. Levofloxacin tablets USP, 500 mg are peach colored capsule shaped, biconvex film-coated tablets, debossed with ‘12’ on one side and ‘T’ on the other side. Levofloxacin tablets USP, 750 mg are white capsule shaped, biconvex film-coated tablets, debossed with ‘11’ on one side and ‘T’ on the other side. Tablets: 250 mg, 500 mg, and 750 mg

Source: FDA prescribing information (DailyMed). Set ID: 5a65b2bc-9edc-f193-e063-6394a90a0104. SPL document ID: 5a65b2c4-0961-618e-e063-6294a90aefaa. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Levofloxacin (FDA label)

The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling: Disabling and Potentially Irreversible Serious Adverse Reactions [see Warnings and Precautions (5.1) ] Tendinitis and Tendon Rupture [see Warnings and Precautions (5.2) ] Peripheral Neuropathy [see Warnings and Precautions (5.3) ] Central Nervous System Effects [see Warnings and Precautions (5.4) ] Exacerbation of Myasthenia Gravis [see Warnings and Precautions (5.5) ] Other Serious and Sometimes Fatal Reactions [see Warnings and Precautions (5.6) ] Hypersensitivity Reactions [see Warnings and Precautions (5.7) ] Hepatotoxicity [see Warnings and Precautions (5.8) ] Risk of Aortic Aneurysm and Dissection [see Warnings and Precautions (5.9) ] Clostridium difficile -Associated Diarrhea [see Warnings and Precautions (5.10) ] Prolongation of the QT Interval [see Warnings and Precautions (5.11) ] Musculoskeletal Disorders in Pediatric Patients [see Warnings and Precautions (5.12) ] Blood Glucose Disturbances [see Warnings and Precautions (5.13) ] Photosensitivity/Phototoxicity [see Warnings and Precautions (5.14) ] Development of Drug Resistant Bacteria [see Warnings and Precautions (5.15) ] Crystalluria and cylindruria have been reported with quinolones, including levofloxacin.

Source: FDA prescribing information (DailyMed). Set ID: 5a65b2bc-9edc-f193-e063-6394a90a0104. SPL document ID: 5a65b2c4-0961-618e-e063-6294a90aefaa. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Levofloxacin (FDA label)

Levofloxacin tablets are contraindicated in persons with known hypersensitivity to levofloxacin, or other quinolone antibacterials [see Warnings and Precautions (5.3) ]. Known hypersensitivity to levofloxacin tablets or other quinolones (4 , 5.7)

Source: FDA prescribing information (DailyMed). Set ID: 5a65b2bc-9edc-f193-e063-6394a90a0104. SPL document ID: 5a65b2c4-0961-618e-e063-6294a90aefaa. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Levofloxacin (FDA label)

Anaphylactic reactions and allergic skin reactions, serious, occasionally fatal, may occur after first dose ( 4 , 5.7 ) Hematologic (including agranulocytosis, thrombocytopenia), and renal toxicities may occur after multiple doses ( 5.6 ) Hepatotoxicity: Severe, and sometimes fatal, hepatotoxicity has been reported. Discontinue immediately if signs and symptoms of hepatitis occur (5.8) Clostridium difficile -associated colitis: evaluate if diarrhea occurs ( 5.10 ) Prolongation of the QT interval and isolated cases of torsade de pointes have been reported. Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) 5.1 Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and Tendon Rupture, Peripheral Neuropathy, and Central Nervous System Effects Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient.

Source: FDA prescribing information (DailyMed). Set ID: 5a65b2bc-9edc-f193-e063-6394a90a0104. SPL document ID: 5a65b2c4-0961-618e-e063-6294a90aefaa. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Levofloxacin (FDA label)

Interacting Drug Interaction Multivalent cation-containing products including antacids, metal cations or didanosine Absorption of levofloxacin is decreased when the tablets are taken within 2 hours of these products. (2.4 , 7.1) Warfarin Effect may be enhanced. Monitor prothrombin time, INR and watch for bleeding (7.2) Antidiabetic agents Carefully monitor blood glucose ( 5.13 , 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired.

Source: FDA prescribing information (DailyMed). Set ID: 5a65b2bc-9edc-f193-e063-6394a90a0104. SPL document ID: 5a65b2c4-0961-618e-e063-6294a90aefaa. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.